Baseline tumor characteristics
| Characteristic . | No. (%) . |
|---|---|
| Total | 63 (100) |
| Stage IV St Jude/Murphy | 63 (100) |
| Karyotype | 24 (38) |
| t(8;14) | 22 (88) |
| t(8;22) | 2 (8) |
| t(2;8) | 1 (4) |
| Ig-myc only | 13 (54) |
| Hyperploid | 3 (12) |
| “B” symptoms | 51 (81) |
| ECOG | |
| 2 or less | 24 (38) |
| More than 2 | 39 (62) |
| LDH less than normal range (N) | 3 (5) |
| 2 to 5N | 32 (51) |
| More than 5N | 28 (44) |
| Bulky tumor | 19 (30) |
| Peripheral blasts | 17 (27) |
| BM blasts | 50 (79) |
| BM blasts more than 25% | 48 (76) |
| CNS* | 48 (76) |
| CSF leukemia | 12 (19) |
| Cranial nerve palsy | 36 (57) |
| Epidural mass | 10 (16) |
| BM and CNS disease | 37 (59) |
| Liver | 28 (44) |
| GI tract | 19 (30) |
| Kidney | 10 (16) |
| Patients with other sites | 28 (44) |
| IPI | |
| 2 | 6 (9) |
| 3 | 13 (21) |
| 4 | 42 (67) |
| 5 | 2 (3) |
| Characteristic . | No. (%) . |
|---|---|
| Total | 63 (100) |
| Stage IV St Jude/Murphy | 63 (100) |
| Karyotype | 24 (38) |
| t(8;14) | 22 (88) |
| t(8;22) | 2 (8) |
| t(2;8) | 1 (4) |
| Ig-myc only | 13 (54) |
| Hyperploid | 3 (12) |
| “B” symptoms | 51 (81) |
| ECOG | |
| 2 or less | 24 (38) |
| More than 2 | 39 (62) |
| LDH less than normal range (N) | 3 (5) |
| 2 to 5N | 32 (51) |
| More than 5N | 28 (44) |
| Bulky tumor | 19 (30) |
| Peripheral blasts | 17 (27) |
| BM blasts | 50 (79) |
| BM blasts more than 25% | 48 (76) |
| CNS* | 48 (76) |
| CSF leukemia | 12 (19) |
| Cranial nerve palsy | 36 (57) |
| Epidural mass | 10 (16) |
| BM and CNS disease | 37 (59) |
| Liver | 28 (44) |
| GI tract | 19 (30) |
| Kidney | 10 (16) |
| Patients with other sites | 28 (44) |
| IPI | |
| 2 | 6 (9) |
| 3 | 13 (21) |
| 4 | 42 (67) |
| 5 | 2 (3) |
GI indicates gastrointestinal.
Some patients had several neurologic involvements.